PathologyWatch’s Contrarian Play: Why Building a Full-Stack Healthcare Company Beat the Pure SaaS Route
When entering a regulated market like healthcare, conventional startup wisdom suggests building a pure software solution. It’s cleaner, more scalable, and typically commands higher multiples. But in a recent Category Visionaries episode, PathologyWatch CEO Daniel Lambert revealed why they took the opposite approach – and how that decision proved crucial to their success.
The Default Path Wasn’t Working
PathologyWatch initially tried the traditional route. As Daniel explains, “We had initially tried to develop an AI and then think about licensing it to different parties, but the industry was not really ready for that.” This early experience forced them to reconsider their entire approach to market entry.
The Full-Stack Revelation
The pivot came after extensive customer research. After interviewing dozens of dermatologists, they consistently heard the same message: “Don’t bring us just a point of the solution or like a piece of it. We get pitched all the time on just a single device or a single thing. What we want is for you to pick up our biopsies, handle everything end to end, show us the digital image, integrate with our electronic medical record system.”
This led to a crucial insight about healthcare innovation: “The best way to break in, and this is true, especially in healthcare, is to start as a tech enabled service company, more so than just trying to be the SaaS technology provider, which means you’re sacrificing some upside on the multiples, but it also means that you can actually handle the patient case directly.”
Learning Through Operations
Running their own labs proved invaluable for product development. As Daniel notes, “We really needed to run the labs. We really needed to run these algorithms on our own and develop these algorithms in our own lab so that we can learn from all of those things. And in healthcare, you’re dealing with biology, and it’s a lot of unknown things when you start a company like this.”
This hands-on experience revealed challenges they wouldn’t have discovered otherwise: “We had to actually sell the process of this, actively working to catch smudges and bad stains and artifacts that come out of the lab. And that if you’re really going to be an AI developer in this space, you have to think about the realities and not just build an AI on a very clean data set.”
The Market Validation
The decision to build a full-stack solution has been validated by rapid market adoption. In just two and a half years of active selling, PathologyWatch has secured 180 clinics and three hospital partnerships. Their approach has resonated particularly well with dermatologists, who appreciate the seamless integration and comprehensive service.
Why It Worked: The Power of Embracing Complexity
The success of PathologyWatch’s full-stack approach reveals an important truth about healthcare innovation: sometimes the fastest path to disruption is through embracing, rather than avoiding, industry complexity. By handling everything from sample collection to digital analysis and EMR integration, they’ve built deep relationships with customers while developing better technology.
As Daniel explains, “Everybody has a plan until you get punched in the face. We really needed to run the labs… so that we can learn from all of those things.” This willingness to get their hands dirty with day-to-day operations has given them insights that pure software companies might miss.
For founders considering entering regulated markets, PathologyWatch’s journey offers a compelling alternative to the pure SaaS playbook. Sometimes, the path to building a category-defining company requires taking on more complexity, not less. While this approach might mean sacrificing some theoretical multiple expansion, it can lead to faster market adoption and deeper competitive moats in industries where operational expertise matters as much as technical innovation.